Revita Procedure (Fractyl): Keeping Weight Off After GLP-1

What is the Revita procedure, and can it really keep the weight off after you stop a GLP-1? Revita is a one-time endoscopic procedure from Fractyl Health that treats the lining of the duodenum, the first part of the small intestine. In its pivotal REMAIN-1 study, people who stopped tirzepatide and had Revita regained 5.1% of body weight at six months, compared with 8.2% after a sham procedure. It is not FDA-approved yet. Fractyl plans to file with the FDA in late 2026 and hopes for a US launch in early 2028.

Revita was in the news twice this week. On October 16, 2026, Fractyl announced the six-month pivotal results. On October 22, it said it would cut about 45% of its workforce and put all its focus on Revita. Here is what the results mean for someone on Zepbound, Wegovy or Ozempic who worries about life after the shots.

Why weight regain after stopping GLP-1 is the problem Revita targets

Stopping a GLP-1 usually brings weight back. In the SURMOUNT-4 trial, people who switched from tirzepatide to placebo regained about 14% of their body weight within a year. In the STEP 1 extension, people regained about two-thirds of the weight they had lost on semaglutide one year after stopping. We cover the details in our GLP-1 rebound research guide.

That is why "post-GLP-1 weight maintenance" has become its own market. Many people stop because of cost, side effects or insurance changes. Revita is one of the first products built just for that moment.

How the Revita procedure works

Fractyl's idea is that years of excess weight and high blood sugar change the lining of the duodenum, which helps sense food and sends hormone signals. Resurfacing it is meant to restore healthier signaling. That theory is still being tested.

Fractyl Revita REMAIN-1 results, in plain English

REMAIN-1 is a randomized, double-blind, sham-controlled study at more than 30 US sites. Here is how the pivotal cohort worked:

1. Adults with obesity (no type 2 diabetes) took tirzepatide, the drug in Zepbound and Mounjaro, for an average of 25 weeks and lost an average of 18.3% of body weight.
2. They stopped tirzepatide.
3. They were randomly assigned, two to one, to Revita or a sham procedure. Neither the patients nor the people measuring them knew which one they got.

The main difference was statistically significant (p=0.0023, 308 people in the analysis). Fractyl says the gap between the groups nearly doubled from month 3 to month 6.

Fractyl also points to people who got a longer treatment (20 cm or more of the duodenum), who regained 3.8%. That was a post hoc analysis, meaning it was not the main planned test, so treat it as a clue, not a result.

Three things to keep in mind:

• Revita slowed regain. It did not stop it. Both groups gained weight back.
• These are company numbers. The data are not yet peer reviewed or checked by the FDA.
• Six months is short. The second main goal, whether more than half of patients keep at least 5% weight loss at one year, reports in Q1 2027. Investors were not impressed: Fractyl's stock fell more than 60% on the day of the release.

Revita side effects and safety

Fractyl reports no device- or procedure-related serious adverse events, no deaths and no unexpected device effects through the September 24, 2026 data cut-off. Side effects linked to the procedure were mostly mild and happened right around it, with about 94% within seven days. The company has not published a full side effect list yet.

Any endoscopy has risks, and sedation is usually used. Talk to a gastroenterologist about what applies to you. If you are pregnant, under 18 or have a history of an eating disorder, any weight procedure needs a doctor's close review.

Revita FDA approval timeline and cost

There is no US price. A billing code does not mean insurance will pay. Until approval, the only legitimate way to get Revita in the US is a clinical trial.

Revita vs other ways to keep weight off after a GLP-1

You do not have to wait until 2028 to protect your results. The habits that matter most are the ones you build while you are still on the drug: enough protein, regular strength work and honest tracking. Sharpy sets one daily protein target, gives you one 20-minute workout and turns your progress into a Shape Score, so you can see whether you are keeping muscle, not just losing pounds. Our guide on how to stop a GLP-1 without rebound walks through the plan step by step, and resistance training on GLP-1 shows where to start.

What Revita means for you right now

• If you are on a GLP-1 and doing well, nothing changes. Do not stop or change your dose because of this news. That is a talk with your prescriber.
• If you are about to stop, ask your doctor about a maintenance plan and whether a Revita trial is open near you.
• If you see Revita sold for cash in the US outside a trial, walk away.

Revita is a promising idea with real but modest early data. The one-year results in early 2027 will tell us much more. For now, keep the muscle you have: Sharpy helps you hit protein and train every day, on the drug and after it.

Sources

• Fractyl Health: Revita meets six-month co-primary endpoint in REMAIN-1 pivotal study (Oct 16, 2026)
• Fractyl Health 8-K: Sharpens focus on Revita following positive pivotal results (Oct 22, 2026)
• Aronne et al., SURMOUNT-4, JAMA 2024
• Wilding et al., STEP 1 extension, Diabetes Obes Metab 2022
• ClinicalTrials.gov